The Relationship between the Levels of Serum Cystatin C and the Occurrence of the No-Reflow Phenomenon during Primary Percutaneous Coronary Interventions | ||
| The Medical Journal of Cairo University | ||
| Volume 91, Issue 06, June 2023, Pages 897-908 PDF (588.02 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mjcu.2023.319011 | ||
| Authors | ||
| RASHA ADEL THABET, M.D.** and MARIAM AL-FEKY, M.D., F.R.C.S. (Glasgow)* ROFYDA O. FATHALLAH, M.Sc.*; HUSSEIN Sh. EL MARKABI, M.D.*;1; ABDELRAHMAN E. ATTIA, M.D. and ADEL M. SHABANA, M.D. HOSSAM EL-DIN E.M. FARRAG, M.B.B.Ch.; AHMED Sh. ELSERAFY, M.D.;2 | ||
| 1The Departments of Ophthalmology* and Pediatrics**, Faculty of Medicine, Ain Shams University | ||
| 2The Department of Cardiology, Faculty of Medicine, Ain Shams University | ||
| Abstract | ||
| Abstract Background: The best treatment of ST-segment elevation myocardial infarction (STEMI) is reperfusion of ischemic myocardium as soon as possible. Primary percutaneous coro-nary intervention (PPCI) has become the preferred strategy for reperfusion and the current standard care for STEMI. No-reflow is clinically important as it is associated with cardiac failure, malignant arrhythmias and in-hospital and long-term mortality. Cystatin C is a potent inhibitor of lysosomal pro-teinases and found in virtually all tissues and body fluids. Aim of Study: To assess the relationship between the level of Cystatin C and the occurrence of no-reflow during primary PCI in the setting of STEMI. Patients and Methods: This study was carried out at the Cardiology Department Ain Shams University. This prospective clinical trial study was conducted on 68 patients with acute STEMI who were undergoing PPCI who were subdivided into 2 groups: Group 1: Patients with TIMI III flow. Group 2: Patients with no reflow. Serum cystatin c level was assessed in the group with TIMI III flow VS No reflow group from May 2022 till October 2022. Results: There was statistically significant difference between reflow and no reflow regarding cystatin c level found higher in no reflow cases than reflow cases. Conclusion: In conclusion, data of this study suggest that Cystatin C is a useful marker for prediction of no-reflow after PCI in STEMI as it can help in screening of STEMI patients with high risk of development of no-reflow on admission and help to choose the best treatment. | ||
| Keywords | ||
| Cystatin C; No reflow; ST elevation myocardial infarction | ||
|
Statistics Article View: 261 PDF Download: 174 |
||
